Skip to search formSkip to main contentSkip to account menu

INCB024360

Known as: INCB 024360 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

epacadostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 3809: T-cell activation through the inhibition of tumor-expressed IDO1 activity in tryptophan metabolism pathway
Indoleamine 2,3-dioxygenase-1 (IDO1) has been described as a major mechanism of immunosuppression in tumors. Despite histologic… 
2018
2018
Abstract 5555: Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers
Indoleamine-2,3-dioxygenase (IDO1) is well-recognized as an important target for immunotherapeutic intervention. Growing… 
2017
2017
Highlights of This Issue
Last prior treatment The enzyme indoleamine 2,3dioxygenase-1 (IDO1), which catabolizes tryptophan degradation, can promote tumor… 
2016
2016
Abstract 3209: CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models
CRLX101, an investigational nanoparticle-drug conjugate (NDC) containing the payload camptothecin, is currently being clinically… 
2016
2016
Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor
Drug–drug interaction (DDI) studies involving warfarin are typically conducted with subtherapeutic doses of warfarin to ensure… 
2015
2015
Abstract 4469: A novel class of inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) with potential for the treatment of cancer
A broad range of cancers express the tryptophan catabolising enzyme indoleamine 2,3-dioxygenase 1 (IDO1) as a mechanism of… 
Highly Cited
2015
Highly Cited
2015
Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
Meeting abstracts Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme that is expressed in many cancers and… 
Highly Cited
2014
Highly Cited
2014
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
3010 Background: Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme that is overexpressed in cancers and… 
2013
2013
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
3025 Background: INCB024360 is a potent, selective inhibitor of IDO1. As the catabolism of tryptophan (Trp) to kynurenine (Kyn… 
2013
2013
Abstract C42: Development and validation of an IHC-based detection method for studying indoleamine 2,3-dioxygenase 1 (IDO1) expression in human cancers.
Indoleamine 2,3-dioxygenase-1 (IDO1) mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)